F4/80 Antibody (Cl:A3-1 (recombinant version)) [HRP]
Novus Biologicals, part of Bio-Techne | Catalog # NBP2-81030H
Recombinant Monoclonal Antibody
Conjugate
Catalog #
Forumulation
Catalog #
Key Product Details
Species Reactivity
Mouse
Applications
Flow Cytometry, Immunohistochemistry
Label
HRP
Antibody Source
Monoclonal Rat IgG2b Kappa Clone # Cl:A3-1 (recombinant version)
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
This F4/80 Antibody (Cl:A3-1 (recombinant version)) was developed against Thioglycollate stimulated peritoneal macrophages of mouse origin.
Clonality
Monoclonal
Host
Rat
Isotype
IgG2b Kappa
Theoretical MW
160 kDa.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Applications for F4/80 Antibody (Cl:A3-1 (recombinant version)) [HRP]
Application
Recommended Usage
Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Immunohistochemistry
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A purified
Formulation
PBS
Preservative
No Preservative
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: F4/80
Depending on factors such as differentiation, activation, and location, the level of F4/80 expression can vary between cell-types (1,2). For example, peritoneal macrophages are subdivided based on morphology and expression with large peritoneal macrophages having high levels of F4/80 and small peritoneal macrophages having low F4/80 expression (1). Furthermore, splenic macrophages are classified based on location (red pulp, marginal zone, and white pulp) and F4/80 expression level varies within these populations as well; the red pulp macrophages have high levels of F4/80 and CD68 by comparison (1). Originally, the F4/80 monoclonal antibody was generated for a macrophage-specific surface antigen, however F4/80 staining is also observed in other hematopoietic cell populations, thus other immune cell markers should be used in conjunction with F4/80 to distinguish between different populations (1). Though the full extent of F4/80 ligands and biological functions remains elusive, studies have suggested that F4/80 is critical for macrophage-natural killer cell interaction and cytokine release (1,2). Additionally, a study of anterior chamber-associated immune deviation (ACAID) indicated a possible role for F4/80 in the generation of regulatory T cells (1,2).
References
1. Dos Anjos Cassado A. (2017). F4/80 as a Major Macrophage Marker: The Case of the Peritoneum and Spleen. Results and Problems in Cell Differentiation. https://doi.org/10.1007/978-3-319-54090-0_7
2. Hamann, J., Hsiao, C. C., Lee, C. S., Ravichandran, K. S., & Lin, H. H. (2016). Adhesion GPCRs as Modulators of Immune Cell Function. Handbook of Experimental Pharmacology. https://doi.org/10.1007/978-3-319-41523-9_15
Alternate Names
DD7A5-7, Gpf480, Ly71
Gene Symbol
Adgre1
Additional F4/80 Products
Product Documents for F4/80 Antibody (Cl:A3-1 (recombinant version)) [HRP]
Product Specific Notices for F4/80 Antibody (Cl:A3-1 (recombinant version)) [HRP]
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...